ERBB2 and neoplasm: Several other in vitro studies have confirmed the antineoplastic properties of monoclonal antibodies directed against HER2 expressing tumor cells demonstrated by inhibition of anchorage-dependent growth [89, 90], monolayer tumor growth [91], and colonies in soft agar [91–93] or by sensitizing the HER2 overexpressing cells to tumor necrosis factor alpha [92].